Top Story

Iluvien for DME poised to fulfill unmet need, create significant market niche

March 26, 2015

The Iluvien intravitreal implant will satisfy an unmet need among patients with diabetic macular edema and create sizeable new markets, Alimera Sciences officials said during a company-sponsored webcast.

Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg) is a non-bioerodable device designed to release fluocinolone acetonide at an initial rate of 0.25 µm per day for 36 months.

Breaking News

House passes bill to repeal sustainable growth rate

March 26, 2015
By a vote of 392 to 37, the U.S. House of Representatives passed a bipartisan bill today that repeals the sustainable growth rate, a key factor in annual Medicare…
In the Journals

Retaine ophthalmic emulsion may improve dry eye signs, symptoms

March 26, 2015
Retaine ophthalmic emulsion may be an effective therapy to reduce signs and symptoms of dry eye, according to a study.The single-center, open-label study evaluated 42…
VIDEO BLOG: Bridging the reimbursement gap, part 1 BlogVideo

VIDEO BLOG: Bridging the reimbursement gap, part 1

March 26, 2015
In part 1 of "Bridging the reimbursement gap," Cynthia A. Matossian, MD, discusses the patient visit that first motivated her to introduce over-the-counter products…
The Young Ophthalmologist: Learn DMEK based on protocols from NIIOS

The Young Ophthalmologist: Learn DMEK based on protocols from NIIOS

March 26, 2015
With the exception of a few staunch holdouts, almost everyone now agrees: Compared with conventional Descemet’s stripping endothelial keratoplasty, Descemet’s membrane…
More News Headlines »
Practical Retina

Comparing Aflibercept, Bevacizumab, and Ranibizumab for DME: Analysis of DRCR Protocol T

Ophthalmic Surgery, Lasers and Imaging Retina
Online Advanced Release, March 5, 2015
More »
CME
Real World Use of Anti-VEGF Therapy

Real-World Use of Anti-VEGF Therapy

This activity is supported by an educational grant from Genentech, Inc.

Recent approvals have expanded clinicians’ options for the management of diabetic eye disease. Anti-VEGF therapy…
More »
Meeting News Coverage Video
thumbnail for video 4131356728001

VIDEO: Speaker discusses the advantages of swept source OCT

March 24, 2015
At Retina 2015, SriniVas Sadda, MD, discusses the advantages of swept source OCT over existing commercial SD-OCT…
More »
morganatic-roan
morganatic-roan